We Claim:

1. A pharmaceutical composition for treatment of neuropathic pain comprising: Palmitoylethanolamide (PEA) and one or more naturally occurring Fatty Acid Amide Hydrolase (FAAH) Inhibitor.

2. The pharmaceutical composition as claimed in claim 1, wherein the amount of PEA ranges from 35 to 80% by wt. of the composition.

3. The pharmaceutical composition as claimed in claim 1, wherein the amount of naturally occurring FAAH inhibitor ranges from 0.5 to 40% by wt. of the composition.

4. The pharmaceutical composition as claimed in claim 1, wherein the naturally occurring FAAH Inhibitor is selected from Myricetin, Isorhamnetin, Kaempferol, Biochanin A, Genistein, Daidzein or a combination thereof.

5. The pharmaceutical composition as claimed in claim 4, wherein the naturally occurring FAAH inhibitor is selected from Daidzein, Genistein or combination thereof.

6. The pharmaceutical composition as claimed in any of the preceding claims, further comprising vitamins, coenzymes or a combination thereof.

7. The pharmaceutical composition as claimed in claim 6, wherein the vitamins are selected from methylcobalamin, cyanocobalamin, benfotiamine or a combination thereof; and co-enzymes are selected from ubidecarenone, thiamine pyrophosphate, Flavin adenine dinucleotide or a combination thereof.

8. The pharmaceutical composition as claimed in claim 6, wherein the amount of vitamins ranges from 0.01 to 30% by wt. of the composition.

9. The pharmaceutical composition as claimed in claim 6, wherein the amount of coenzymes ranges from 10 to 40% by wt. of the composition.

10. The pharmaceutical composition as claimed in any of the preceding claims, further comprising pharmaceutically acceptable excipients.

11. The pharmaceutical composition as claimed in claim 10, wherein the pharmaceutically acceptable excipient is selected from a diluent, disintegrant, binder, solubilizing agent, lubricant, glidant, or solvent.

12. The pharmaceutical composition as claimed in claim 11, wherein the amount of diluent ranges from 5% to 50% by wt. of the composition, disintegrant ranges from 0.5% to 10 % by wt. of the composition, binder ranges from 0.1% to 10% by wt. of the composition, solubilizing agent ranges from 0.25% to 15% by wt. of the composition, lubricant ranges from 1.0% to 10% by wt. of the composition, glidant ranges from 1.0% to 10% by wt. of the composition, or amount of solvent is quantity sufficient.

13. The pharmaceutical composition as claimed in claim 1, wherein the composition is in the form of a tablet, capsule, sachet, pill, hard capsule filled with liquid or solid, soft capsule, powder, granule, suspension solution or modified release formulation.

14. A process for preparing a pharmaceutical composition as claimed in claim 1 comprising:

a. weighing accurately all the ingredients in separate containers,
b. sifting previously weighed PEA, Natural FAAH Inhibitor(s), diluent(s), and a disintegrating agent(s) separately,
c. mixing content of step b,
d. preparing binder solution in separate container and add it to step c and sieve the dough to obtain granules,
e. drying the obtained granulates until the level of dryness (LOD) is reduced to less than 1.5 % w/w,
f. sifting semi dried granules through suitable sieve,
g. sifting previously weighed lubricant(s) or glidant(s) separately through suitable sieve and add to step f.